The impact of belatacept on third‐party HLA alloantibodies in highly sensitized kidney transplant recipients
暂无分享,去创建一个
M. Kamoun | C. Larsen | M. Ford | T. Pearson | M. Levine | R. Bray | H. Gebel | F. Eun-Hyung Lee | I. Badell | Dong-feng Chen | H. C. Sullivan | R. Parsons | Annette M. Jackson | Arslan M Zahid | Shalini Bumb | Hannah Decker | Idelberto Raul Badell
[1] S. Knechtle,et al. Dual targeting: Combining costimulation blockade and bortezomib to permit kidney transplantation in sensitized recipients , 2018, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[2] J. Friedewald,et al. Prognostic tools to assess candidacy for and efficacy of antibody‐removal therapy , 2018, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[3] R. Bray,et al. Comparison of de novo IgM and IgG anti‐HLA DSAs between belatacept‐ and calcineurin‐treated patients: An analysis of the BENEFIT and BENEFIT‐EXT trial cohorts , 2018, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[4] A. Waterman,et al. Kidney exchange match rates in a large multicenter clearinghouse , 2018, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[5] H. Meier‐Kriesche,et al. Posttransplant reduction in preexisting donor‐specific antibody levels after belatacept‐ versus cyclosporine‐based immunosuppression: Post hoc analyses of BENEFIT and BENEFIT‐EXT , 2018, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[6] H. Meier‐Kriesche,et al. De novo donor‐specific antibodies in belatacept‐treated vs cyclosporine‐treated kidney‐transplant recipients: Post hoc analyses of the randomized phase III BENEFIT and BENEFIT‐EXT studies , 2018, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[7] F. Pirenne,et al. Control of Humoral Response in Renal Transplantation by Belatacept Depends on a Direct Effect on B Cells and Impaired T Follicular Helper-B Cell Crosstalk. , 2018, Journal of the American Society of Nephrology : JASN.
[8] R. Montgomery,et al. IgG Degrading Enzyme of Streptococcus Pyogenes: An Exciting New Development in Desensitization Therapy. , 2018, Transplantation.
[9] M. Stegall,et al. Kidney Transplant With Low Levels of DSA or Low Positive B-Flow Crossmatch: An Underappreciated Option for Highly Sensitized Transplant Candidates , 2017, Transplantation.
[10] C. Nast,et al. IgG Endopeptidase in Highly Sensitized Patients Undergoing Transplantation , 2017, The New England journal of medicine.
[11] R. Bray,et al. Understanding solid-phase HLA antibody assays and the value of MFI. , 2017, Human immunology.
[12] R. Redfield,et al. Kidney transplantation of highly sensitized recipients under the new kidney allocation system: A reflection from five different transplant centers across the United States. , 2017, Human immunology.
[13] D. Phelan,et al. HLA compatibility assessment and management of highly sensitized patients under the new kidney allocation system (KAS): A 2016 status report from twelve HLA laboratories across the U.S. , 2017, Human immunology.
[14] C. Larsen,et al. Costimulation Blockade in Autoimmunity and Transplantation: The CD28 Pathway , 2016, The Journal of Immunology.
[15] M. Miller,et al. Delayed Cytotoxic T Lymphocyte–Associated Protein 4–Immunoglobulin Treatment Reverses Ongoing Alloantibody Responses and Rescues Allografts From Acute Rejection , 2016, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[16] R. Formica,et al. Changes in Deceased Donor Kidney Transplantation One Year After KAS Implementation , 2016, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[17] Joshua Pyke,et al. Allocating Deceased Donor Kidneys to Candidates with High Panel-Reactive Antibodies. , 2016, Clinical journal of the American Society of Nephrology : CJASN.
[18] L. Rostaing,et al. Belatacept and Long-Term Outcomes in Kidney Transplantation. , 2016, The New England journal of medicine.
[19] Hao Wu,et al. Long-Lived Plasma Cells Are Contained within the CD19(-)CD38(hi)CD138(+) Subset in Human Bone Marrow. , 2015, Immunity.
[20] L. Garrett-Sinha,et al. CD28 Promotes Plasma Cell Survival, Sustained Antibody Responses, and BLIMP-1 Upregulation through Its Distal PYAP Proline Motif , 2015, The Journal of Immunology.
[21] A. Kirk,et al. Costimulation Blockade Alters Germinal Center Responses and Prevents Antibody‐Mediated Rejection , 2014, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[22] A. Bingaman,et al. Single‐Center Kidney Paired Donation: The Methodist San Antonio Experience , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[23] L. Kucirka,et al. Desensitization in HLA-incompatible kidney recipients and survival. , 2011, The New England journal of medicine.
[24] L. Rostaing,et al. A Phase III Study of Belatacept‐based Immunosuppression Regimens versus Cyclosporine in Renal Transplant Recipients (BENEFIT Study) , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[25] K. Kokko,et al. Transplanting the Highly Sensitized Patient: The Emory Algorithm , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[26] N. Fineberg,et al. Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics1 , 2004, Transplantation.
[27] R. Montgomery,et al. Specific and durable elimination of antibody to donor HLA antigens in renal-transplant patients , 2003, Transplantation.
[28] D. Churchill,et al. Comparison of mortality risk for dialysis patients and cadaveric first renal transplant recipients in Ontario, Canada. , 2000, Journal of the American Society of Nephrology : JASN.